NOTICE OF INTENT TO SOLE SOURCE: The Centers for Disease Control and Prevention (CDC) announces its intention to negotiate a sole source award with the Oxford Immunotec, Marlborough, MA. CDC has an on-going study to compare the Tuberculin skin testing (TST) to Interferon-gamma release assays (IGRA). The Tuberculosis Elimination Study Constortium (TBESC)'s two main study objectives are to evaluate and compare the performance of TSTs and IGRAs in (1) diagnosing latent TB Infection (LTBI); and, (2) predicting progression from LTBI to TB Disease including subgroups of patients. As part of this study, different IGRAs will be employed. Both QuantiFERON® TB Gold In-Tube (QFT-G In-Tube) as well as T-SPOT TB. The purpose of this requirement is to contract T-SPOT.TB tests. The anticipated performance period is seven (7) year with one base period of 12 months and six (6) option periods of 12 months each. Oxford Immunotec is the sole proprietor of the T-SPOT TB and is also FDA Approved. Therefore, CDC intends to negotiate this requirement with Oxford Immunotec under the authority of FAR 6.302-1 and HHSAR 306.302-1, Only One Responsible Source, and 41 U.S.C. 253(c)(1). This notice of intent is not a request for competitive proposals. A determination to compete this procurement based on a response to this notice is solely within the discretion of the Government. Interested parties who believe they possess the capabilities to satisfy this requirement should submit a capability statement demonstrating their abilities to meet this requirement. All responses should be received by the June 15, 2012, at 4 PM, Eastern Standard Time (EST). All responses must be in writing and can be sent via email to
[email protected] or faxed to 770-488-2868. No phone calls will be accepted.